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Abstract
Objective: Insulin resistance, diabetes, and hypertension are considered elements of metabolic syndrome which is
associated with vascular dysfunction. We investigated whether inhibition of protein kinase C (PKC) would affect
vascular function in diabetic hypertensive (DH) rats.
Methods: A combination of type 2 diabetes and arterial hypertension was produced in male Sprague Dawley rats by
intrauterine protein deprivation (IUPD) followed by high salt diet. At the age of 32 weeks, DH rats were treated for 2
weeks with the angiotensin-converting enzyme inhibitor captopril (Capto, 30 mg/kg), PKC inhibitor ruboxistaurin
(RBX, 50 mg/kg) or vehicle (n = 8 per group) and blood pressure was monitored using telemetry. At the end of
experiments, femoral arteries were dissected, and vascular reactivity was evaluated with isovolumic myography.
Results: The IUPD followed by high salt diet resulted in significant elevation of plasma glucose, plasma insulin, and
blood pressure. Endothelium-dependent vascular relaxation in response to acetylcholine was blunted while vascular
contraction in response to phenylephrine was enhanced in the DH rats. Neither Capto nor RBX restored
endothelium-dependent vascular relaxation while both suppressed vascular contraction. Ex-vivo incubation of
femoral arteries from control rats with insulin induced dose-response vasorelaxation while insulin failed to induce
vasorelaxation in the DH rat arteries. In the control arteries treated with endothelial nitric oxide synthase inhibitor
L-NAME, insulin induced vasoconstriction that was exacerbated in DH rats. Capto and RBX partially inhibited
insulin-stimulated vascular contraction.
Conclusion: These findings suggest that PKC inhibition ameliorates functional endothelial insulin resistance and
smooth muscle cell hypersensitivity to insulin, but does not restore acetylcholine-activated endothelium-dependent
vasodilation in DH rats.
Introduction
Insulin resistance, type 2 diabetes, and hypertension are
often clustered as part of metabolic syndrome [1].
Endothelial dysfunction is a salient and, likely a unifying
feature of metabolic syndrome that translates systemic
risk factors into vascular pathology [2]. It has been
recently recognized, however, that endothelial dysfunc-
tion is far more complex than blunted endothelium-
dependent vasodilation in response to acetylcholine or
blood flow (shear stress). Specifically, endothelial insulin
resistance appears to be one of the key mechanisms of
vascular dysfunction in metabolic syndrome and a major
cause of atherosclerosis [3-5].
Protein kinase C (PKC) is intimately involved in devel-
opment of vascular insulin resistance and vascular dys-
function [6]. Ruboxistaurin (RBX), a PKC inhibitor, has
been widely used to study vascular function in animal
models related to metabolic syndrome and in clinical
research [4,7-9]. Many questions regarding vascular
effects of PKC inhibition, however, remain unanswered.
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First, it is unclear whether PKC inhibition uniformly or
differentially regulates vascular response to insulin and
“classical” vasoreactive substances (e.g., acetylcholine
and epinephrine). Second, while the role of PKC in
endothelial dysfunction is well documented, less is
known about smooth muscle cell (SMC) response to
insulin. Third, available data related to vascular insulin
resistance is largely of biochemical nature and there is a
lack of complementary data on vascular function.
Fourth, vascular insulin resistance has been primarily
studied in models of metabolic syndrome driven by
genetic defects that may potentially skew the results and
jeopardize clinical translation.
Here, we analyzed the influence of pharmacological
PKC inhibition on vascular function in a model that
combines diabetes and hypertension, while angiotensin-
converting enzyme (ACE) inhibitor Captopril (Capto)
was used as a positive control in the blood pressure por-
tion of the study [10]. We utilized the rat model of
intrauterine protein deprivation (IUPD) followed up by
the long term administration of high salt diet as
described previously [2,10,11]. In this model, diabetes
and hypertension are induced by a combination of rele-
vant non-genomic factors that are applied in the pre-
and post-natal periods which reflect the complex envir-
onmental origins of metabolic syndrome.
Materials and methods
The animal experiments were conducted in accordance
with the guidelines of Institute of Laboratory Animal
Research Guide, Public Health Service Policy, Animal
Welfare Act, and an approved IACUC protocol of Eli
Lilly and Company.
In vivo manipulations
A total of 24 male rats that underwent intrauterine pro-
tein deprivation (IUPD) and age matched control rats
were obtained from Charles River Laboratories. In brief,
IUPD rats were obtained from female Sprague Dawley
(SD) rats placed on TD.90016 diet (6%protein) 2 weeks
before mating, during pregnancy, lactation, and until
weaning (Figure 1). Eight additional control rats were
derived from female SD rats maintained on normal
rodent chow (20% protein).
All IUPD rats underwent pressure transmitter implan-
tation surgery after a 2 week acclimation period (see
schematic of study design in Figure 1). The transmitters
(model TA11PA-C40; Data Sciences International, St.
Paul, MN) were surgically implanted in iliac artery using
a method previously described [12]. At age of 9 weeks
(Figure 1), all instrumented rats were placed on a high
salt (6%) diet (Test Diet 0009386) and became diabetic
hypertensive (DH). Two weeks post surgery, baseline
blood pressure data were measured. Digitized pressure
signals were acquired for 30 s every 10 min using DSI
Dataquest IV 2.0 software. Mean pressure was calculated
as the arithmetic mean of the sample waveform sampled
at a frequency of 500 Hz. The digitized values were
stored and manipulated on a Compaq 486/33 MHz
computer.
At the age of 32 weeks, DH rats were assigned to one
of three groups (n = 8): vehicle, the ACE inhibitor
Capto 30 mg/kg or PKC inhibitor RBX 50 mg/kg. Both
Capto and RBX were administered as an admixture in
the diet used for the controls (Test Diet 0009386) for 2
weeks (Figure 1). The body weights and food consump-
tion were measured weekly.
Plasma samples were collected by cardiac draw at the
termination of the study. Glucose, free fatty acid (FFA)
and triglyceride levels were analyzed by a Hitachi analy-
zer model 912 (Roche, Indianapolis, IN). A rat sensitive
insulin kit (Millipore Bioscience Division St. Charles,
MO) was used to determine insulin levels.
Isovolumic myography for endothelial and vascular
smooth muscle functions
The vascular function data presented below were intended
to unravel the potential effects of PKC inhibition on arter-
ial endothelial and SMC function. At termination day, the
animals were anesthetized with isofluorane. The common
femoral arteries were harvested and the animal was eutha-
natized with over-dose of anesthesia. The excised vessels
were immediately stored in 4°C HEPES physiologic saline
solution (HEPES-PSS, pH7.4, in mmol/l: 142 NaCl, 4.7
KCl, 2.7 HEPES Na, 3 HEPES, 1.17 MgSO4, 2.79 CaCl, 5.5
Glucose; HEPES and HEPES Na were purchased from
Sigma, while others were purchased from Fisher Scientific,
USA). The blood was sampled and the plasma was sepa-
rated and stored at -80°C. The arterial segment was care-
fully cleaned from adjacent tissue with the aid of a stereo-
dissection microscope. The branches on the artery were
ligated and the vessel was allowed to warm up to room
temperature (22°C) slowly in 10-15 min. The vessel was
transferred to the chamber of isovolumic system and can-
nulated with connectors and secured with 8-0 suture twice
to avoid any leakage. The vessel was warmed up to 37°C
slowly (20-25 min) and equilibrated for 40 min at a trans-
mural pressure of 25 mmHg before agonist and antagonist
stimulation.
A novel isovolumic method was recently introduced
that has the physiology of pressure myograph with sensi-
tivity of wire myograph to evaluate the vasoreactivity of
small and large vessels [13,14]. Briefly, the femoral vessel
was cannulated on both ends in a bath with HEPES-PSS
and incubated at 37°C. The vessel was stretched to in situ
length and pre-loaded at physiologic pressure of
70 mmHg and pharmacologically induced contraction or
relaxation with both ends closed. The contraction or
Lu et al. Cardiovascular Diabetology 2011, 10:48
http://www.cardiab.com/content/10/1/48
Page 2 of 11
relaxation of the vessel wall against the luminal fluid
increases or decreases the pressure, respectively. The
pressure was measured with a pressure transducer
(Mikro-Tip SPR-524, Millar Instruments, USA) and
external diameter was measured with a dimensional tra-
cer (DiamTrak 3+, Australia). The typical tracing curves
of pressure and diameter during vasoreactivity were
represented in Figure 2.
Endothelium-dependent relaxation to Acetylcholine
The arterial segment was contracted to an approximate
transluminal pressure (150 ± 15 mmHg) with a submax-
imal dose of phenylephrine (10-7 to 10-6 mol/L). There-
after, the endothelium-dependent dose-response
relaxation was induced with a series of doses of acetyl-
choline (ACh) from 10-9 to 10-6 mol/L.
Insulin- and acetylcholine-induced vasorelaxation
The arterial segment was contracted to transluminal
pressure of 150 ± 15 mmHg with a submaximal dose of
phenylephrine (10-7 to 10-6 mol/L). Insulin was added to
the bath at concentrations of 10-11 to 10-8 mol/L. After
insulin induced vasorelaxation, acetylcholine dose-
response (10-9 to 10-6 mol/L) was administered follow-
ing maximal concentration of insulin.
Relaxation in response to exogenous nitric oxide (NO)
The arterial segment was contracted to an approximate
transluminal pressure (150 ± 15 mmHg) with a
submaximal dose of phenylephrine (10-7 to 10-5 mol/L).
The endothelium-independent relaxation to verify the
sensitivity of vascular smooth muscle to NO was induced
with a series of doses of sodium nitroprusside (SNP): 10-9
to 10-5 mol/L.
Vasoconstriction to adrenergic agonist
The dose response contractile tension to phenylephrine
was performed at a series of dose: 10-8 to 10-5 mol/L.
Insulin-induced vasoconstriction in the absence of NO
The vessel segment was incubated with the endothelial
NO synthase (eNOS) inhibitor Nω-nitro-L-arginine
methyl ester (L-NAME, 10-5 mol/l) for 30 min. Insulin
was added to the bath at concentrations of 10-11 to
10-8 mol/L.
Baseline Vasoreactivity
Non-receptor specific contraction to potassium chlor-
ide (KCl, 60 mmol/L) and vasorelaxation in response
to calcium-free were measured to verify the calcium-
mediated contraction and relaxation of vascular
smooth muscle.
Data analysis and Statistics
The circumferential tension of the vessel at every dose
was calculated by Laplace’s equation, tension = pressure
× inner radius. The inner radius was calculated using
the incompressibility assumption [14]. The % decrease
Figure 1 Schematic of the study design.
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Figure 2 The typical tracing curves of pressure and diameter versus time during vasoreactivity which were measured by isovolumic
myograph. A: The endothelium-dependent dose-response vasorelaxation. The vessels were contracted by phenylephrine (PE) to approximate
pressures and relaxed by a series of doses of acetylcholine (ACh) (top panel) or a series of doses of ACh following by a series doses of insulin
(bottom panel). B: The dose-response vasoconstriction in response to PE (top panel) and insulin with presentation of L-NAME (bottom panel).
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in tension was calculated by the equation: %Relaxation
= (Td - Ti)/(Tmax - Ti)× 100, where, Td, Ti, and Tmax are
the tension at every dose of vasodilators (Td), physiolo-
gical level (Ti), and maximum tension (Tmax) at at a
sub-maximal concentration of phenylephrine, respec-
tively. The agonist concentration that produced 50% of
the maximal vasorelaxation (IC50) and vasoconstriction
(EC50) was calculated. Data were presented as mean ±
standard deviation and significant differences between
groups were determined by Student’s t-test (two-tailed
distribution, two-sample unequal variance). Significant
differences between the dose-dependent groups were
determined by Two-way ANOVA between groups (fol-
lowing Bonferroni test). A probability of p < 0.05 was




Body weight and triglycerides were not significantly differ-
ent in any of the groups (Table 1). Plasma glucose, insulin,
and FFA were significantly elevated in DH rats (Table 1).
The treatments with Capto and RBX did not have a signif-
icant effect on these plasma parameters. Blood pressure
(Figure 3) was significantly increased in DH rats in com-
parison with that in SD rats (97 ± 11 mmHg). As
expected, Capto exerted anti-hypertensive effects while
RBX treatment did not change blood pressure [10].
Endothelial function
The endothelium-dependent vascular relaxation in
response to acetylcholine was blunted in DH rats.
Neither Capto nor RBX treatment restored the endothe-
lium-dependent vascular relaxation (Figure 4A and
Table 2). Ex vivo incubation of femoral arteries from
control rats with insulin induced dose-response vasore-
laxation. Insulin failed to induce vasorelaxation in the
DH rat arteries. Capto and RBX treatment were able to
restore vasodilatory response to insulin (Figure 4B).
These results indicate that IUPD followed by high salt
diet lead to endothelial insulin resistance at least
partially mediated by Renin Angiotensin System (RAS)
and PKC signaling.
Surprisingly, in the presence of insulin, endothelium-
dependent vascular relaxation in response to ACh was
fully restored in all experimental groups (Figure 5 and
Table 2). To the best of our knowledge, this is a new
phenomenon that is not completely understood and
requires further study.
SMC function
Endothelium-independent vascular relaxation in
response to exogenous NO (sodium nitroprusside) was
blunted in the DH rats. Treatment with either Capto or
RBX did not significantly affect response to exogenous
NO (Figure 4C and Table 2). Vascular contraction in
response to a-adrenergic agonist (phenylephrine) was
enhanced in the DH rats. Both Capto and RBX treat-
ment suppressed vascular contraction in response to
phenylephrine (Figure 6A and Table 3). These findings
are consistent with SMC functional change concomitant
with but independent of endothelial dysfunction.
We also analyzed direct, NO-independent, effects of
insulin on SMC by blocking NO with L-NAME (Figure
6B and Table 3). Interestingly, insulin induced paradoxi-
cal vasoconstriction in the presence L-NAME in all
groups. When NO was blocked, the vascular contraction
was amplified in the DH rats and treatment with Capto
and RBX did not significantly suppress insulin-induced
vascular contraction (Figure 6B). Finally, we tested the
non-receptor dependent vasoreactivity to normalize
SMC function. Dose of 35 and 60 mmol/L KCl HEPES-
PSS were applied to induce vascular contraction and
Calcium (Ca2+)-free HEPES-PSS with EGTA (3 mmol/L,
Ca2+ chelator) was used to induced vascular relaxation.
The KCl-induced vascular contraction was not signifi-
cantly different in various groups (Figure 7A and Table
3). The Ca2+ free induced vascular relaxation was also
not significantly different in various groups (Figure 7B).
This confirms that endothelial dysfunction and SMC
functional changes found in IUPD rats are not attribu-
ted to technical artifacts.
Table 1 Systemic effects of drug treatment in DH rats
SD rat DH rat
Vehicle Vehicle Capto RBX
Body Weight (grams) 539.2 ± 43.3 573.8 ± 49.1 566.4 ± 46.6 566.1 ± 45.6
Glucose (mg/dl) 129.4 ± 8.65 284.5 ± 38.5* 278.7 ± 28.7* 284.0 ± 22.7*
Trigl yceride (mg/dl) 122.5 ± 18.14 135.2 ± 48.5 130.8 ± 50.8 98.2 ± 42.2
Insulin (mg/dl) 1.42 ± 0.462 2.23 ± 1.97* 2.07 ± 1.46* 1.50 ± 0.787
FFA (mg/dl) 223.6 ± 84.2 660.7 ± 170.6* 483.5 ± 152.6* 462.7 ± 145.4*
Notes: FFA: free fatty acid; Capto: captopril treatment; RBX: ruboxistaurin treatment; SD: Sprague Dawley rat; DH: diabetic hypertension. * indicates statistical
difference in comparison with control (P < 0.05).
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Discussion
The major finding of this study is that PKC mediates
endothelial insulin resistance and vascular smooth mus-
cle hypersensitivity to insulin in DH rats. PKC, however,
does not seem to be involved in acetylcholine-mediated
vasodilation. The implications and limitations of these
findings are elaborated.
Endothelial dysfunction (impaired endothelium-depen-
dent vasorelaxation in response to blood shear stress or
acetylcholine) is a salient feature of patients with meta-
bolic syndrome, type 2 diabetes, and hypertension [2,3].
The epidemiologic observations that smaller size at
birth is associated with increased rates of coronary heart
disease, stroke, type 2 diabetes, adiposity, and metabolic
syndrome in adult life have been extensively replicated
[15]. IUPD rat is widely used as an animal model of
developmentally programmed metabolic syndrome [16].
Endothelial dysfunction has also been described in the
IUPD rat model [17]. In the current study, we used the
rat model that combined IUPD and postnatal exposure
to high salt and have extended observations of endothe-
lial dysfunction to these conditions [10,11,18]. More-
over, we demonstrated that this endothelial dysfunction
due to impaired acetylcholine-dependent vasodilation
was accompanied by endothelial insulin resistance and
SMC hyper contractility in response to both pheny-
lephrine and insulin.
From vascular function point of view, endothelial
insulin resistance is manifested by paradoxical contrac-
tion of the artery in response to insulin stimulation.
Intracellular insulin signaling is mediated by two major
pathways, Phosphoinositide (PI)3-kinase/Akt and mito-
gen-activated protein kinase (MAPK). The former
induces NO production and, therefore, leads to vasore-
laxation [3]. The latter, however, is associated with the
downstream release of endothelin 1 (ET1) that is consis-
tent with vasoconstriction. In the insulin-sensitive
endothelial cells, these pathways are well balanced, and
Figure 3 High salt fed IUPD rats develop arterial hypertension (P < 0.05 in comparison with SD rats). The mean pressure of SD rats was
97 ± 11 mmHg. Capto treatment significantly decreased blood pressure (P < 0.05), while RBX did not affect blood pressure (P > 0.05). n = 7; *:
P < 0.05 vs. vehicle treated DH rats at the time point. #: P < 0.05 vs. RBX treated DH rats using two way ANOVA.
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insulin stimulation is usually associated with weak vaso-
dilation. Insulin resistance is known to be pathway-
selective; i.e., it affects primarily PI3-kinase signaling
and either spares or even enhances MAPK/ET1 signal-
ing [3]. As a result, the net effect of insulin is swayed
towards vasoconstriction.
It has been demonstrated that endothelial insulin
resistance in other animal models of metabolic syn-
drome, e.g., Zucker fatty rats, diabetic mice, and neona-
tal rats with high glucose, was mediated by PKC-b
[4,18-20]. Most likely, PKC induces insulin resistance by
serine phosphorylation of insulin receptor substrate(s)
that prevents insulin-induced tyrosine phosphorylation
and thus blocks insulin signaling [21]. RBX treatment
restored Akt phosphorylation and NO production in
response to insulin in the Zucker fatty rats [4]. Our
functional data based on pharmacological inhibition of
PKC by RBX indicate that PKC activation is also critical
for endothelial insulin resistance in the femoral artery of
DH rat.
It is unclear how PKC is activated in the arteries of
DH rats. Angiotensin II (AngII) type 1 receptor signal-
ing might be the most pertinent in this context
[12,22,23]. AngII intracellular signaling involves both
calcium and diacylglycerol generation that is consistent
with downstream activation of conventional and novel
PKC isoforms [22]. AngII is known to induce vascular
insulin resistance in a PKC-dependent manner [24]. Our
data demonstrated that both Capto and RBX indepen-
dently conferred vascular benefits. It is unlikely though
that angiotensin II signaling is solely mediated by PKC.
It is equally unlikely that angiotensin II is the only
upstream signal that activates PKC in the vasculature of
DH rats. Alternatively, it is plausible that elevated blood
glucose and fatty acids are metabolized into diacylgly-
cerol in the vascular wall, and metabolically produced
diacylglycerol stimulates PKC [6]. In the current study,
we used Capto as a positive control treatment for the
blood pressure portion of the study rather than a true
mechanistic tool. Future mechanistic studies are neces-
sary to understand possible relationships between
AngII-dependent and independent mechanisms of vas-
cular PKC activation.
Surprisingly, we have observed clear dichotomy
between drug effects on endothelial insulin resistance
and endothelial dysfunction due to impaired acetylcho-
line-dependent vasodilation. While endothelial insulin
resistance was completely ameliorated by Capto and
RBX alike, neither compound was able to restore arterial
response to acetylcholine. Arguably, this phenomenon
may reflect differential effects of complex DH rat milieu
on NO production and release. The IUPD rat was dia-
betic and therefore more complicated than sponta-
neously hypertensive (SH) rat [25]. It was reported that
Figure 4 Analysis of vasorelaxation. A: Endothelium-dependent
vasorelaxation in response to acetylcholine while vessel was pre-
constricted with phenylephrine (PE). SD+V: Vehicle treated Sprague-
Dawley rats. H+V: Vehicle treated DH rats. H+C: Captopril treated
DH rats. H+R: RBX treated DH rats. B: Vascular relaxation in response
to insulin while vessel was pre-constricted with PE. C: Endothelium-
independent vasorelaxation in response to SNP while vessel was
pre-constricted with PE. n = 7; *: P < 0.05 vs. vehicle treated of SD
rats at the doses. #: P < 0.05 vs. vehicle treated SD rats using
ANOVA.
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Capto prevented impaired endothelial response to acet-
ylcholine in SH rats, while antihypertensive treatment
did not restore endothelial function in rats with hyper-
tension and diabetes [26-28]. We have also recently
shown that restoration of endothelial response to acetyl-
choline in Zucker diabetic fatty rats required activation
of peroxisome proliferation-activated receptor g, thereby
suggesting that this part of endothelial function in dia-
betic rats is regulated in an angiotensin-independent
manner [29]. Future studies are required for deeper
mechanistic understanding of this phenomenon.
It is also unclear why exogenous insulin improved
endothelial response to acetylcholine in every group. It
is possible that insulin may act at the level of NO
Table 2 Maximal vasorelaxations and concentrations elicited half-maximal vasorelaxation to acetylcholine (ACh),
insulin, ACh with insulin, and sodium nitroprusside (SNP)
Ach Insulin Ach + Insulin SNP
Groups Max, % IC50(× 10
-7M) Max, % IC50(× 10
-10M) Max, % IC50(× 10
-7M) Max, % IC50(× 10
-8M)
SD+V 116 ± 22 1.2 ± 0.8 17 ± 12 1.1 ± 1.2 116 ± 17 0.6 ± 0.5 103 ± 20 2.4 ± 1.7
H+V 67 ± 13* 1.3 ± 0.7 6 ± 7* 140+122* 98 ± 15 0.7 ± 0.6 83 ± 17 43 ± 3.1
H+C 65 ± 15* 1.8 ± 0.9 21 ± 10† 3.3 ± 3.8† 88 ± 13 1.3 ± 0.9 83 ± 16 1.7 ± 0.9
H+R 73 ± 14* 1.6 ± 0.9 22 ± 11† 1.5 ± 1.8† 98 ± 11 1.4 ± 0.9 88 ± 15 2.2 ± 1.2
Notes: SD+V: Vehicle treated Sprague-Dawley rats. H+V: Vehicle treated DH rats. H+C: Captopril treated DH rats. H+R: ruboxistaurin treated DH rats. * indicates
statistical difference in comparison with SD+V (P < 0.05). † indicates statistical difference in comparison with H+V (P < 0.05).
Figure 5 Endothelium-dependent vasorelaxation with presence of insulin. A: Vehicle treated SD rats. The presence of insulin increased the
vasorelaxation at low doses (P < 0.05). SD+V: Vehicle treated Sprague-Dawley rats. H+V: Vehicle treated DH rats. H+C: Capto treated DH rats. B:
Vehicle treated DH rats. The presence of insulin increased the vasorelaxation at most doses (P < 0.05). C: Capto treated DH rats. The presence of
insulin increased the vasorelaxation at every dose (P < 0.05). D: RBX treated DH rats. The presence of insulin increased the vasorelaxation at
every dose (P < 0.05). n = 7; *: P < 0.05 vs. without presence of insulin at the doses. #: P < 0.05 vs. without presence of insulin using ANOVA.
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production. Agonists, including acetylcholine and brady-
kinin, are known to induce endothelial NO release from
eNOS activation mediated in a calcium-dependent man-
ner [30,31]. In diabetes where eNOS activity is impaired,
there is less NO to be released in response to a given
dose of acetylcholine [1,6]. Insulin stimulates Akt phos-
phorylation and thereby activates eNOS [1,3]. Therefore,
less acetylcholine may be needed to induce vasodilation
in the presence of insulin. Phenomenon of insulin-
dependent improvement of acetylcholine-induced vaso-
dilation is also reported in the clinic [32,33]. It would be
intriguing to study effects of RBX on endothelial insulin
sensitivity in the clinic to complement existing data
solely focusing on the endothelial dysfunction due to
impaired acetylcholine-dependent vasodilation [7-9].
This approach becomes even more appealing in light of
new data demonstrating, that in isolated, genetically
induced endothelial insulin resistance (mediated by
endothelial-specific insulin receptor knock-out),
Figure 6 Vascular contractile tension during vasoconstriction in
response to a-adrenergic receptor agonist (phenylephrine, PE)
and insulin. A: PE-induced vascular contraction. SD+V: Vehicle
treated Sprague-Dawley rats. H+V: Vehicle treated IUPD hypertensive
rats. H+C: Captopril treated IUPD hypertensive rats. B: Insulin-
induced vascular contraction while eNOS was blocked with L-NAME.
n = 6; *: P < 0.05 vs. vehicle treated of SD rats at the doses. #: P <
0.05 vs. vehicle treated SD rats using ANOVA.
Table 3 Maximal constriction and concentrations elicited
half-maximal vasoconstriction to phenylephrine and
insulin with L-NAME
Phenylephrine Insulin + L-NAME 60 mM KCl
Groups Max, % EC50(× 10
-
7M)
Max, % EC50(× 10
-6M) Max, %
SD+V 9.5 ± 2.2 2.5 ± 0.5 5.8 ± 1.1 3.9 ± 2.2 12 ± 3.1
H+C 16 ± 2.2* 3.1 ± 0.6 6.8 ± 1.2* 0.011 ± 0.035* 13 ± 2.4
H+C 8.7 ± 2.1† 2.3 ± 0.4 6.2 ± 1.6 0.006 ± 0.009* 12 ± 1.2
H+R 11 ± 1.9† 11 ± 3*† 6.4 ± 0.8 6.3 ± 5.2† 13 ± 0.9
Notes: SD+V: Vehicle treated Sprague-Dawley rats. H+V: Vehicle treated DH
rats. H+C: Captopril treated DH rats. H+R: ruboxistaurin treated DH rats. *
indicates statistical difference in comparison with SD+V (P < 0.05). † indicates
statistical difference in comparison with H+V (P < 0.05).
Figure 7 Non-receptor dependent vasoreactivity. A: Vascular
constriction in response to potassium chloride (KCl). SD+V: Vehicle
treated Sprague-Dawley rats. H+V: Vehicle treated DH rats. There
was no statistical difference between groups (P > 0.05). H+C: Capto
treated IUPD hypertensive rats. B: Vasorelaxation in response to
Calcium absent HEPES-PSS while vessel was pre-constricted with
phenylephrine (PE). There was no statistical difference between
groups (P > 0.05).
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dramatically enhanced development of atherosclerosis in
an ApoE-deficient mice model [33].
The current study is the first attempt to address the role
of PKC in a very complex non-genomic model related to
metabolic syndrome. In follow-up studies, it is necessary
to unravel relative contribution of individual risk factors
(IUPD, high salt and age) that are known to have direct
and indirect effects on vascular function as well as specific
PKC isoforms involved in differential vascular response to
various stimuli [12,17,34-36]. It is equally important to
identify biochemical mechanisms of the observed func-
tional phenomena. Nevertheless, defining PKC as a key
regulator of vascular functional response to insulin pro-
vides important directions for future experimental and,
potentially, clinical studies aiming at preventing vascular
complications of metabolic disorders.
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